Evaluation of serological and hematological parameters in donors of SARS-CoV-2 convalescent plasma of respect to time periods of donation
, 1, 1, 2
Abstract
Introduction: The COVID-19 pandemic has had a major impact on the health and lives of many people worldwide. According to World Health Organization (WHO) global data, 774 million cases of COVID-19 and 7.04 million COVID-19 deaths have been reported. Many people are still struggling with the consequences of infection with SARS-CoV-2. In the first months of the COVID-19 pandemic, understanding the pathophysiology of the new SARS-CoV-2 virus and establishing effective therapies became the priority. Due to the lack of dedicated treatment against SARS-CoV-2 and the limited availability of antiviral drugs, Poland was one of many countries that decided to start convalescent plasma therapy. Many COVID-19 convalescents have decided to donate whole blood and plasma.
Material and methods: In our study, we examined how the level of anti-SARS-CoV-2 antibodies changed up to 120 days after suffering from COVID-19 and developing a primary immune response, and whether the hematological parameters of convalescent donors changed significantly during this time. The study group consisted of 394 blood donors whose serum anti-SARS-CoV-2 antibody titers were analyzed via ELISA IgG assay. Additionally, hematological parameters were determined in whole blood samples.
Results: Our research shows that in blood donors who recovered from COVID-19, and whose initial anti-SARS-CoV-2 antibody levels were high, these high levels persisted even to the 120th day after the onset of the disease. Also, the hematological parameters remain normal, enabling safe blood donation for the donor and the recipient despite the previous presence of COVID-19.
Conclusions: These results can be used to optimize the parameters qualifying donors to donate convalescent plasma in the event of the future emergence of new infectious agents with significant infectivity and mortality.
Keywords: Convalescent plasmaCOVID-19SARS-CoV-2treatmentblood donor
References
- Asselah T, Durantel D, Pasmant E, et al. COVID-19: Discovery, diagnostics and drug development. J Hepatol. 2021; 74(1): 168–184.
- Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from COVID-19. N Engl J Med. 2021; 384(11): 1015–1027.
- Gągola K. Receiving of SARS-CoV-2/COVID-19 convalescent plasma in 2020–2021 in context of activity of Regional Center of Blood Donation and Blood Treatment in Bydgoszcz, Poland. Acta Haematol Pol. 2022; 53(5): 326–334.
- Wang Y, Huo P, Dai R, et al. Convalescent plasma may be a possible treatment for COVID-19: A systematic review. Int Immunopharmacol. 2021; 91: 107262.
- Andrews HS, Herman JD, Gandhi RT. Treatments for COVID-19. Annu Rev Med. 2024; 75: 145–157.
- Yuan Y, Jiao B, Qu L, et al. The development of COVID-19 treatment. Front Immunol. 2023; 14: 1125246.
- Park JW, Lagniton PNP, Liu Yu, et al. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021; 17(6): 1446–1460.
- Chavda VP, Bezbaruah R, Valu D, et al. Adenoviral vector-based vaccine platform for COVID-19: current status. Vaccines (Basel). 2023; 11(2): 432.
- Chavda VP, Bezbaruah R, Dolia S, et al. Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update. Process Biochem. 2023; 127: 66–81.
- Iannizzi C, Chai KLi, Piechotta V, et al. Convalescent plasma for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023; 5(5): CD013600.
- Moog R. COVID 19 convalescent plasma: Is there still a place for CCP? Transfus Apher Sci. 2023; 62(2): 103680.
- Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in COVID-19: Possible mechanisms of action. Autoimmun Rev. 2020; 19(7): 102554.
- Richier Q, De Valence B, Chopin D, et al. Convalescent plasma therapy in immunocompromised patients infected with the BA.1 or BA.2 omicron SARS-CoV-2. Influenza Other Respir Viruses. 2024; 18(3): e13272.
- Filippatos C, Ntanasis-Stathopoulos I, Sekeri K, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis on randomized controlled trials. Viruses. 2023; 15(3): 765.
- Garraud O, Heshmati F, Pozzetto B, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016; 23(1): 39–44.
- Bloch EM, Focosi D, Shoham S, et al. Guidance on the use of convalescent plasma to treat immunocompromised patients with coronavirus disease 2019. Clin Infect Dis. 2023; 76(11): 2018–2024.
- Kumar NR, Karanam VC, Kumar S, et al. Convalescent plasma therapy in late-state, severe COVID-19 infection. South Med J. 2023; 116(5): 427–433.
- Rozporządzenie Ministra Zdrowia w sprawie warunków pobierania krwi od kandydatów na dawców krwi i dawców krwi. Dziennik Ustaw Rzeczypospolitej Polskiej. 2017; 1741: poz. 1741.
- Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. 2022; 28(11): 2406–2415.
- Pawłowska M, Styczyński J. Convalescent plasma: reaching into the past to find answers to new problems. Acta Haematol Pol. 2022; 53(5): 301–302.
- Chauhan L, Pattee J, Ford J, et al. A multicenter, prospective, observational, cohort-controlled study of clinical outcomes following coronavirus disease 2019 (COVID-19) convalescent plasma therapy in hospitalized patients with COVID-19. Clin Infect Dis. 2022; 75(1): e466–e472.
- Casadevall A, Joyner MJ, Pirofski LA, et al. Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. Expert Rev Respir Med. 2023; 17(5): 381–395.
- Skorek A, Jaźwińska-Curyłło A, Romanowicz A, et al. Assessment of anti-SARS-CoV-2 antibodies level in convalescents plasma. J Med Virol. 2022; 94(3): 1130–1137.
- Flisiak R, Horban A, Jaroszewicz J, et al. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. Pol Arch Intern Med. 2021; 131(5): 487–496.
- Agencja Oceny Technologii Medycznych i Taryfikacji WŚOZ. Przegląd doniesień naukowych dla stosowania osocza ozdrowieńców w leczeniu COVID-19. Warszawa, 2021.
- Balcells ME, Rojas L, Le Corre N, et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med. 2021; 18(3): e1003415.
- Salazar E, Christensen PA, Graviss EA, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020; 190(11): 2290–2303.
- Larkey NE, Ewaisha R, Lasho MA, et al. Limited correlation between SARS-CoV-2 serologic assays for identification of high-titer COVID-19 convalescent plasma using FDA thresholds. Microbiol Spectr. 2022; 10(4): e0115422.
- Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity. 2020; 53(5): 925–933.e4.
- Mehew J, Johnson R, Roberts D, et al. Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020. Euro Surveill. 2020; 25(45): 2001754.
- Jungbauer C, Weseslindtner L, Weidner L, et al. Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations. Transfusion. 2021; 61(1): 12–16.
- Gniadek TJ, Thiede JM, Matchett WE, et al. SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease. Transfusion. 2021; 61(1): 17–23.
- Klein SL, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020; 130(11): 6141–6150.
- Körper S, Jahrsdörfer B, Corman VM, et al. Donors for SARS-CoV-2 convalescent plasma for a controlled clinical trial: donor characteristics, content and time course of SARS-CoV-2 neutralizing antibodies. Transfus Med Hemother. 2021; 48(3): 137–147.
